Canal-U

Mon compte

Résultats de recherche

Nombre de programmes trouvés : 17144
Label UNT Conférences

le (9m46s)

Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Target populations: How do we risk-stratify? Are additional biomarkers helpful?

Title : Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Target populations: How do we risk-stratify? Are additional biomarkers helpful?Speaker: Wolfgang KOENIG, Ulm, GERDiscussant: Adrian HERNANDEZ, Durham, USAAbstract : LDL cholesterol (LDL-C) is causally involved in the atherosclerotic process and presents the major lipid variable for risk assessment, and statin therapy is guided by different levels of target LDL-C according to the absolute risk of the patient. Statins have revolutionized the treatment of hypercholesterolemia in patients without but also with manifest atherosclerosis and numerous trials since 4S have consistently documented a decrease in cardiovascular risk associated with decreases in LDL-C. Thus, ...
Voir la vidéo
Label UNT Conférences

le (57m35s)

Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : SHIfTing evidence in heart failure management.

Title : Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : SHIfTing evidence in heart failure management.Speaker: Jeffrey BORER, New York, USAAbstract : SHIFT (Systolic Heart failure treatment with the If inhibitor ivabradine Trial) involved 6505 patients with moderate to severe heart failure (HF), heart rate ?70bpm in sinus rhythm, at least one HF hospitalization during the year prior to study, and LVEF ?35% who were receiving guidelinesbased HF therapy including maximized beta blockade, who were randomized to add either placebo or ivabradine (pure HR slowing drug) during a median 22.9 months follow-up. The results of SHIFT unambiguously demonstrated the benefits of HR ...
Voir la vidéo
Label UNT Conférences

le (10m31s)

Cardiovascular Clinical Trialists (CVCT) Forum – EVOLVE: A major cardiovascular outcomes trial in hemodialysis patients

Title : Cardiovascular Clinical Trialists (CVCT) Forum – EVOLVE: A major cardiovascular outcomes trial in hemodialysis patientsSpeakers: Chris MIX, Amgen, USA - David WHEELER, London, GBRDiscussant: Ziad MASSY, Boulogne-Billancourt, FRAAbstract : EVOLVE: A major cardiovascular outcomes trial in hemodialysis patients.The extracellular calcium-sensing receptor (CaR) was first described in the parathyroid gland. Recent studies have shown that the CaR is also expressed in cardiomyocytes, peri-vascular nerves of the adventitia, vascular smooth muscle cells, and endothelial cells, but our understanding of its physiological functions in the cardiovascular system remains incomplete. A variety of studies point to a possible role of CaR activity modulation ...
Voir la vidéo
Label UNT Conférences

le (11m35s)

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Impact of major clinical trials on ESC Chronic Heart Failure 2012 guidelines. Game changer trials: EMPHASIS-HF, SHIFT, Devices…

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Impact of major clinical trials on ESC Chronic Heart Failure 2012 guidelines. Game changer trials: EMPHASIS-HF, SHIFT, Devices…Speaker: Faiez ZANNAD, Nancy, FRDiscussant: John CLELAND, Hull, GBRAbstract : Impact of major clinical trials on ESC Chronic Heart Failure 2012 guidelines. Game changer trials: EMPHASIS-HF, SHIFT, Devices…L’auteur n’a pas transmis de conflit d’intérêt concernant les données diffusées dans cette vidéo ou publiées dans la référence citée.9th Global Cardiovascular Clinical Trialists Forum • Paris 2012 Multidisciplinary expert workshop : achievements challenges and barriers to implantation of the ESC 2012 chronic heart failure guidelines.Chairpersons: Alain ...
Voir la vidéo
Label UNT Conférences

le (13m33s)

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Omics research and system biology. Keys for future personalized medicine How future trials may help optimizing benefit-to-risk ratio. The role of specialist scientific organizations.

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Omics research and system biology. Keys for future personalized medicineHow future trials may help optimizing benefit-to-risk ratio. The role of specialist scientific organizations.ISCP: Speaker: Felipe MARTINEZ, Cordoba, ARGCVCT: Speaker: Faiez ZANNAD, Nancy, FRAESC Working group in Pharmacology and Drug Therapy : Speaker: Christian TORP-PEDERSEN, Copenhagen, DENAbstract : Cardiovascular medicine and drug development: time for a new trial paradigmOver several decades the event rates in trials have come down and this is frequently attributed to improved treatment of patients. Nevertheless, epidemiological studies of populations have failed to confirm the dramatic decline of ...
Voir la vidéo
Label UNT Conférences

le (13m19s)

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Journal editor’s viewpoints

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Journal editor’s viewpointsSpeaker: Joseph LOSCALZO, Boston, USA, CirculationDiscussant: Rita REDBERG, San Francisco, USA, Arch Intern MedAbstract : L’auteur n’a pas transmis de conflit d’intérêt concernant les données diffusées dans cette vidéo ou publiées dans la référence citée.9th Global Cardiovascular Clinical Trialists Forum • Paris 2012 ESC Working group on cardiovascular pharmacology and drug therapyInternational Society of Cardiovascular Pharmacotherapy (ISCP)CardioVascular Clinical Trialists (CVCT)Joint sessionPERSONALIZED CARDIOVASCULAR MEDICINE AND DRUG DEVELOPMENT: TIME FOR A NEW TRIAL PARADIGMChairpersons: Juan Carlos KASKI, London, GBR - Bertram PITT, Ann Arbor, USA - Luis RUILOPE, Madrid, ESP- “Drugs, ...
Voir la vidéo
Label UNT Conférences

le (3m24s)

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Debate led by Journal Editors: There are too many studies and the quality is variable. Should there be a position statement establishing rules for biomarker studies?

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Debate led by Journal Editors: There are too many studies and the quality is variable.Should there be a position statement establishing rules for biomarker studies?John JARCHO, Boston, USA, NEJMRita REDBERG, San Francisco, USA, Arch Intern MedJoseph LOSCALZO, Boston, USA, CirculationJagat NARULA, New York, USA, JACC imagingMona FIUZAT, Durham, USA, JACC-HFJohn CLELAND, Hull, GBR, Former Eur J Heart FailureAbstract : Debate led by Journal Editors: There are too many studies and the quality is variable.Should there be a position statement establishing rules for biomarker studies?The measurement of biomarkers for diagnosis and prognosis ...
Voir la vidéo
Label UNT Conférences

le (14m5s)

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Resistant hypertension trials: Can renal denervation therapy lower blood pressure?

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Resistant hypertension trials: Can renal denervation therapy lower blood pressure?Speaker: Felix MAHFOUD, Homburg, GERDiscussant: Michel AZIZI, Paris, FRAAbstract : Renal Denervation: Caution is still requiredDespite the availability of multiple classes of orally active antihypertensive treatments, resistant hypertension remains an important public health issue in 2012. The failure of purely pharmacological approaches to treat resistant hypertension has stimulated interest in invasive device-based treatments. A new catheter system using radiofrequency energy has been developed, allowing a percutaneous endovascular approach to renal denervation and providing patients with resistant hypertension with a new therapeutic option. ...
Voir la vidéo
Label UNT Conférences

le (29m25s)

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : National guideline implementation and national registries.

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : National guideline implementation and national registries• NICESpeaker: Suzanna HARDMAN, London, GBR• German CHF registry: REFLECT –HFSpeaker: Carsten TSCHOEPE, Berlin, GER• Eurobservational, the ESC Heart failure RegistrySpeaker: Aldo MAGGIONI, Florence, ITAAbstract : Multidisciplinary expert workshop: achievements, challenges and barriers to implementations of the ESC 2012 chronic heart failureEurobservational Research Program, the ESC Heart Failure Long Term RegistryChronic Heart Failure (HF) is associated with a high burden of mortality and morbidity, reduced quality of life, and increasing healthcare costs in both US and Europe. Evidence-based medicine represents the most effective means of ensuring ...
Voir la vidéo
Conférences

le (1h17m57s)

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Lunch Session 1 : Approvability issues: Pathway to a more global device approval process (Ileana PIÑA)

MODIGLIANI Lunch Debate Session 1 - Friday November 30, 2012THE DEVICE THERAPY TRIALISTS WORKSHOPChairpersons: Gaetano DE FERRARI, Pavia, ITA - Ileana PIÑA, New York, USAWebcast: Tariq AHMAD, Durham, USADevice trial methodology, regulatory and implementation issuesAdvances in interventional medical devices are increasingly affecting cardiovascular therapy, just as pharmacological innovation did the generation before. Yet, designing and conducting a device trial is challenging and drug trial designs may not necessarily be applied fully to device trials.➢ Although there is increasing recognition that this development process substantially differs from that for drugs, how much device trial methodology may deviate from drug trial methodology ...
Voir la vidéo

 
FMSH
 
Facebook Twitter
Mon Compte